-
FPH1 (BRD-6125) Hepatocyte Guide
2026-08-18
A scenario-based guide to using FPH1 (BRD-6125) Hepatocyte Functional Proliferation Enhancer in hepatocyte proliferation, viability, and function assays. It explains how SKU B3701 can support controlled dosing, orthogonal endpoint analysis, and practical vendor selection in primary human hepatocyte culture and iPSC-derived hepatocyte workflows.
-
KX2-361 Blocks BoNT/A SNAP-25 Cleavage
2026-08-18
A 2024 Drug Development Research study shows that the KX2-391 analog KX2-361 suppresses botulinum neurotoxin serotype A activity in motor-neuron and PC12-cell models before and after intoxication. The work combines viability testing, SNAP-25 cleavage assays, intracellular light-chain experiments, and molecular docking to identify KX2-361 as a BBB-relevant lead for intracellular BoNT/A countermeasure development.
-
Adefovir (GS-0393): HBV Research Workflows
2026-08-17
Adefovir (GS-0393) gives researchers a dual-use tool for HBV replication studies and OAT1-mediated renal transport assays. This workflow-focused guide covers mechanism, concentration planning, assay controls, solubility, and interpretation of renal safety signals.
-
Entecavir (BMS200475) for HBV Assays
2026-08-17
Build more reproducible HBV replication assays with Entecavir, from DMSO stock preparation through longitudinal resistance analysis. Its nanomolar activity and utility in wild-type and lamivudine-resistant models make it valuable for both mechanistic screening and translational chronic hepatitis B infection therapy research.
-
Light-Controlled RNA Release for Regulated Gene Therapy
2026-08-16
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that suppresses mRNA translation in darkness and permits therapeutic protein production under blue or ambient light. In AAV-based mouse models, this translation-level switch enabled controllable intervention in diet-induced obesity and retinal neovascular disease, while offering a potential safety mechanism for long-acting gene therapies.
-
KX2-391 and KX2-361: Dual Src–Tubulin Inhibition
2026-08-15
The 2018 Journal of Medicinal Chemistry study describes a discovery strategy for non-ATP-competitive Src inhibitors that target the peptide-substrate binding site and ultimately revealed a second mechanism involving tubulin polymerization. KX2-391 and KX2-361 combined rational modeling, iterative synthesis, cellular pharmacology, and mechanism-of-action studies to generate clinically relevant candidates for actinic keratosis and glioblastoma research.
-
CH 223191: AhR Antagonist for Toxicology
2026-08-14
CH 223191 is a potent aryl hydrocarbon receptor antagonist that suppresses ligand-driven AhR transcription and provides a practical tool for dioxin toxicity mechanism study. In mouse ovarian antral follicles, 1 μM CH 223191 partially rescued MEHP-associated growth, hormone, and gene-expression changes.
-
0.4% Trypan Blue Solution: Practical QC Guide
2026-08-14
0.4% Trypan Blue Solution provides a rapid membrane-integrity readout for cell viability measurement, live/dead cell discrimination, and research cell counting. It is suitable for cell culture and cytotoxicity workflows, but it is not a diagnostic reagent or a standalone method for identifying early apoptosis or specific cell-death mechanisms.
-
BCL-2 Targeting Across Heterogeneous CRPC
2026-08-13
A 2026 study integrates single-cell imaging, mechanistic experiments, therapeutic modeling, and a Phase Ib trial to identify BCL-2 as a shared vulnerability across diverse castration-resistant prostate cancer states. Its findings show that androgen receptor pathway inhibition can increase BCL-2-positive populations, supporting combined AR and BCL-2 targeting rather than an AR-centric strategy alone.
-
GI 254023X: A Causal Assay Framework
2026-08-13
GI 254023X is a selective ADAM10 inhibitor for dissecting sheddase-dependent signaling and endothelial barrier injury. This article develops a causal, cross-assay framework that connects biochemical selectivity with Notch1 signaling, VE-cadherin protection, and evidence-based dose decisions.
-
SAF312 and TRPV1 in Ocular Surface Pain
2026-08-12
The reference study presents SAF312 (Libvatrep) as a potent, selective, noncompetitive TRPV1 antagonist with ocular surface exposure and an acceptable preclinical safety profile. Its integrated pharmacology, pharmacokinetic, toxicology, and corneal wound-healing data support further investigation of localized TRPV1 blockade for ocular surface pain without assuming clinical efficacy.
-
Adefovir (GS-0393) Research Workflows
2026-08-12
Adefovir (GS-0393) combines a defined HBV DNA polymerase mechanism with utility as an OAT1 transporter probe. This guide translates those properties into practical antiviral, renal transport, and translational safety workflows with concentration-aware troubleshooting.
-
KX2-391 Dihydrochloride: Assay Logic
2026-08-11
KX2-391 dihydrochloride is a dual-mechanism Src and tubulin inhibitor with applications spanning oncology, HBV research, and BoNT/A studies. This guide focuses on assay design, evidence boundaries, and how to interpret its distinct cellular phenotypes.
-
Silymarin Workflows for Translational Bench Research
2026-08-11
Build more reproducible oxidative-stress, liver-cancer, metabolic, and antiviral assays with a mixture-aware workflow for Silymarin. Solvent control, dose-ranging, and orthogonal readouts help distinguish genuine biology from vehicle effects and assay interference.
-
(-)-Epigallocatechin gallate (EGCG) Workflow Guide
2026-08-10
Build more reproducible EGCG studies with controlled dosing, fresh solution handling, orthogonal apoptosis readouts, and interference-aware controls. The workflow also shows how parent EGCG findings can inform cancer chemoprevention, antiviral research, antiangiogenesis, and intracellular bacterial assays without overstating translational maturity.